TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes
Each valve was associated with certain benefits, but one-year outcomes were largely similar.
PCI just as successful when patients have a history of TAVR—but there are some added risks
Strokes and bleeding complications are more likely when PCI patients have already undergone TAVR, according to a new analysis of ACC registry data.
Cardiologist highlights safety, effectiveness of Boston Scientific TAVR valve
Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.
When valves fail: Surgeons share advice for treating high-risk patients with TAVR explant and SAVR
When a patient’s TAVR valve fails, redo TAVR is not always a feasible option. TAVR explantation and SAVR are typically the answer in these cases, but that approach is associated with certain risks.
TAVR and SAVR deliver similar outcomes for patients with low-flow, low-gradient aortic stenosis
Paravalvular leak was more common after TAVR, as one may expect, but that was the only notable difference between the two aortic valve replacement strategies. The study's authors did highlight the importance of additional research, including larger studies with longer follow-up periods.

Edwards Lifesciences SAPIEN 3 Ultra TAVR valve

Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes

Each valve was associated with certain benefits, but one-year outcomes were largely similar.

PCI just as successful when patients have a history of TAVR—but there are some added risks

Strokes and bleeding complications are more likely when PCI patients have already undergone TAVR, according to a new analysis of ACC registry data.

Video interview with Andreas Ruck, MD, explaining a SWEDHEART registry comparison of Acurate Neo2 to Sapien and Evolut TAVR valves.

Cardiologist highlights safety, effectiveness of Boston Scientific TAVR valve

Andreas Ruck, MD, discussed new registry data on Boston Scientific’s Acurate neo2 TAVR valve, comparing it to popular devices from Edwards Lifesciences and Medtronic.

When valves fail: Surgeons share advice for treating high-risk patients with TAVR explant and SAVR

When a patient’s TAVR valve fails, redo TAVR is not always a feasible option. TAVR explantation and SAVR are typically the answer in these cases, but that approach is associated with certain risks.

TAVR and SAVR deliver similar outcomes for patients with low-flow, low-gradient aortic stenosis

Paravalvular leak was more common after TAVR, as one may expect, but that was the only notable difference between the two aortic valve replacement strategies. The study's authors did highlight the importance of additional research, including larger studies with longer follow-up periods.

Intravascular lithotripsy IVL carotid artery TAVR

A new use for IVL: helping cardiologists secure transcarotid access for TAVR

IVL can do more than help prep patients for PCI. In fact, one heart team used Shockwave Medical's IVL technology to secure access for a high-risk TAVR patient.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward.

AI predicts LBBB risk in TAVR patients prior to treatment

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

Around the web

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business

U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.